Quote:

---

Personally, I choose to believe, trash the trial, we'll make sure there is a strong buyer for Amarex. Who else could have made such a promise other than those at the gild?

---

As a monotherapy leronlimab was a direct threat to Gilead. As a combo treatment after failed treatment, not really. Other drugs including theirs would still be used in treatment. We were shuffled off to the combo trial because of the viral blips. I wish I had that data so I could try to figure out the causation of those blips.

Leronlimab is a threat to pharma because of it's potential in other diseases. But pharma companies can't seem to grasp that and we can only wonder what Nader was telling them in any discussions.